Commentary|Videos|March 25, 2024
Clinical Benefits With Neratinib in HER2+ Early Breast Cancer
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss the clinical benefits reported with neratinib for the treatment of patients with HER2-positive early breast cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Check out this September recap of OncLive’s coverage of the top news and expert insights in breast cancer.
The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
The top 5 OncLive TV videos of the week.
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
Advertisement
Advertisement
Trending on OncLive
1
Dr Fradley on Real-World Atrial Fibrillation and Cardiovascular Outcomes in CLL
2
Poll Results Highlight Breast Cancer Abstracts of Interest at ESMO 2026
3
FDA Grants Fast Track Designation to Opamtistomig for Advanced Biliary Tract Cancer
4
Dr Hansen on the Integration of CAR T-Cell Therapy Into Earlier Myeloma Treatment Lines
5